The clinical effectiveness agency for England and Wales has said for the second time since July that it will not recommend mifamurtide for young people with a rare bone cancer, saying that the drug is not only costly but that the evidence supporting it cannot easily be compared against standard U.K. practice.Mifamurtide, an immune macrophage stimulant delivered by intravenous infusion, is licensed for the treatment of resectable non-metastatic osteosarcoma after surgery in children, adolescents,...